TARSONS PRODUCTS LIMITED is a Healthcare Equipment & Supplies company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 301 | 296 | 392 | 423 |
| EBITDA (ex other income) | 153 | 100 | 111 | 117 |
| margin % | 50.8 | 33.7 | 28.2 | 27.6 |
| Owners' profit | 101 | 0 | 0 | 0 |
| EPS, as reported (₹) | 19.46 | 8.01 | 5.60 | 2.69 |
| ROE % · ROCE % | 20.6 · 27.3 | 7.0 · 9.3 | 4.7 · 7.1 | 2.3 · 4.8 |
| Debt / equity (x) | 0.04 | 0.42 | 0.52 | 0.60 |
| Cash from operations | 83 | 103 | 114 | 118 |
| Capex | (132) | (184) | (152) | (126) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99 | 96 | 113 | 91 | 102 | 108 | 121 | 110 |
| Profit before tax | 15 | 8 | 16 | 3 | 6 | 8 | 6 | (1) |
| Net profit | 10 | 5 | 10 | 2 | 3 | 5 | 4 | (1) |
| EPS (₹) | 1.93 | 0.99 | 1.92 | 0.34 | 0.62 | 0.95 | 0.79 | (0.27) |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| India | 333 | 78.8 |
| Germany | 90 | 21.2 |
| Intersegment Revenue-India | 0 | 0.0 |
| Total, before eliminations | 423 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Tarsons Products 43rd AGM notice published in newspapers | compliance | minimal | — | — |
| 2 Sept 2026 · Tarsons Products shares AGM notice and FY26 annual report weblink to shareholders | board shareholder meetings | minimal | — | — |
| 2 Sept 2026 · Tarsons Products files BRSR for FY 2025-26 | compliance | minimal | — | — |
| 2 Sept 2026 · 43rd AGM scheduled on September 24, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Tarsons 43rd AGM on Sep 24, 2026 via VC; key items: RPTs with Nerbe and excess pay waiver | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Tarsons Products FY26 Annual Report Revenue up, PAT nearly halves on facility costs | results | high | — | — |
| 25 Aug 2026 · Tarsons Products fixes 43rd AGM for September 24, 2026 | compliance | minimal | — | — |
| 17 Aug 2026 · Q1 FY27 earnings call transcript filed | investor communications | medium | — | — |
| 11 Aug 2026 · Audio recording of Q1 FY27 earnings call uploaded | investor communications | low | — | — |
| 11 Aug 2026 · Tarsons Products Q1 FY27 Financial Results Published in Newspapers | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 2,353 |
| 15.0 |
| 6.11 |
| 43.6 |
| 8.1 |
| 11.3 |
| — |
| 15.5 |
| TARSONS PRODUCTS LIMITED ◆ | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| FABTECH TECHNOLOGIES LTD | 650 | 10.6 | 1.55 | 10.6 | 9.1 | 10.7 | — | 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 149.0 | 20.0 | 16 of 17 | 6% |
| P/B | 2.6 | 2.7 | 5 of 11 | 60% |
| ROCE | 2.4 | 11.3 | 16 of 17 | 6% |
| ROE | 2.3 | 8.1 | 9 of 11 | 20% |
| Debt / Equity | 0.6 | 0.1 | 11 of 11 | 0% |
| EBITDA margin | 29.0 | 16.7 | 3 of 11 | 80% |
| Revenue growth | 20.7 | 13.9 | 4 of 13 | 75% |
| Profit growth | (181.0) | 75.5 | 10 of 10 | 0% |
| Market cap | 1657 | 175 | 3 of 17 | 88% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
